Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

32.83 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116
Open 32.83
Bid (Size) 31.08 (1)
Ask (Size) 33.73 (1)
Prev. Close 32.83
Today's Range 32.83 - 32.83
52wk Range 24.24 - 68.39
Shares Outstanding 67,447,548
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented
bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the EU and UK) in adult, adolescent and... 
From Business Wire News Releases
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET. 
From Business Wire News Releases

Performance

YTD
-26.49%
-26.49%
1 Month
+9.76%
+9.76%
3 Month
+1.36%
+1.36%
6 Month
-25.99%
-25.99%
1 Year
-48.33%
-48.33%

More News

Read More
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
From Business Wire News Releases
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
Notable Monday Option Activity: BLUE, BIGC, GRPN
Tags Stocks
From Market News Video
How The Parts Add Up: FBT Targets $202
Tags ETFs
From ETF Channel
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
From Business Wire News Releases
Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?
Tags TMO NVS Market News
From Motley Fool
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel)
From Business Wire News Releases
AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer
From Business Wire News Releases
FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia
Tags gene therapy Biotech Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.